Hoth Therapeutics Inc (HOTH) Stock Soars After Company Licenses Real-Time, Breath-Based COVID-19 Test

Monday, August 10, 2020 10:45 AM | Nick Dey

Hoth Therapeutics Inc (HOTH) is trading up 11.96% at $3.09 per share so far Monday. HOTH stock is up sharp after they announced the licensing of intellectual property rights related to the development of a breath-based COVID-19 test that will allow health professionals to provide immediate diagnosis of the infection.

Hoth Therapeutics Inc (HOTH) stock has fallen -39.88% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives HOTH stock a score of 37 out of a possible 100.

That score is chiefly influenced by a long-term technical score of 5. HOTH’s score also includes a short-term technical score of 18. The fundamental score for HOTH is 88. In addition to the average rating from Wall Street analysts, HOTH stock has a mean target price of 10. This means analysts expect the stock to gain 223.62% over the next 12 months.

What’s Happening with HOTH Stock Today

Hoth Therapeutics Inc (HOTH) stock has gained 11.92% while the S&P 500 is up 0.17% as of 10:23 AM on Monday, Aug 10. HOTH is up $0.33 from the previous closing price of $2.76 on volume of 8,361,131 shares. Over the past year the S&P 500 is up 16.44% while HOTH has fallen -39.88%. HOTH lost -$0.87 per share in the over the last 12 months.

Share this article:

Related Companies

You May Also Like